-
1
-
-
84858328629
-
Sustained rheumatoid arthritis remission is uncommon in clinical practice
-
Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, Iannaccone CK, Weinblatt ME, Solomon DH. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012, 14:R68.
-
(2012)
Arthritis Res Ther
, vol.14
-
-
Prince, F.H.1
Bykerk, V.P.2
Shadick, N.A.3
Lu, B.4
Cui, J.5
Frits, M.6
Iannaccone, C.K.7
Weinblatt, M.E.8
Solomon, D.H.9
-
2
-
-
77950307115
-
Treating rheumatoid arthritis to target: recommendations of an international task force
-
3015099, 20215140, T2T Expert Committee
-
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, . T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 3015099, 20215140, T2T Expert Committee.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
Breedveld, F.C.4
Boumpas, D.5
Burmester, G.6
Combe, B.7
Cutolo, M.8
de Wit, M.9
Dougados, M.10
Emery, P.11
Gibofsky, A.12
Gomez-Reino, J.J.13
Haraoui, B.14
Kalden, J.15
Keystone, E.C.16
Kvien, T.K.17
McInnes, I.18
Martin-Mola, E.19
Montecucco, C.20
Schoels, M.21
van der Heijde, D.22
more..
-
3
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
2935329, 20444750
-
Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 2935329, 20444750.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 964-975
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
Dougados, M.4
Emery, P.5
Gaujoux-Viala, C.6
Gorter, S.7
Knevel, R.8
Nam, J.9
Schoels, M.10
Aletaha, D.11
Buch, M.12
Gossec, L.13
Huizinga, T.14
Bijlsma, J.W.15
Burmester, G.16
Combe, B.17
Cutolo, M.18
Gabay, C.19
Gomez-Reino, J.20
Kouloumas, M.21
Kvien, T.K.22
Martin-Mola, E.23
McInnes, I.24
Pavelka, K.25
van Riel, P.26
Scholte, M.27
Scott, D.L.28
Sokka, T.29
Valesini, G.30
more..
-
4
-
-
79951506884
-
American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
-
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, et al. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 404-413
-
-
Felson, D.T.1
Smolen, J.S.2
Wells, G.3
Zhang, B.4
van Tuyl, L.H.5
Funovits, J.6
Aletaha, D.7
Allaart, C.F.8
Bathon, J.9
Bombardieri, S.10
Brooks, P.11
Brown, A.12
Matucci-Cerinic, M.13
Choi, H.14
Combe, B.15
de Wit, M.16
Dougados, M.17
Emery, P.18
Furst, D.19
Gomez-Reino, J.20
Hawker, G.21
Keystone, E.22
Khanna, D.23
Kirwan, J.24
Kvien, T.K.25
Landewé, R.26
Listing, J.27
Michaud, K.28
Martin-Mola, E.29
Montie, P.30
more..
-
6
-
-
34447343764
-
Assessing remission in clinical practice
-
Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975-979.
-
(2007)
Rheumatology (Oxford)
, vol.46
, pp. 975-979
-
-
Mierau, M.1
Schoels, M.2
Gonda, G.3
Fuchs, J.4
Aletaha, D.5
Smolen, J.S.6
-
7
-
-
38749151004
-
Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score
-
van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Peeters AJ, van Krugten MV, Breedveld FC, Dijkmans BA, Allaart CF. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2008, 67:266-269.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 266-269
-
-
van der Kooij, S.M.1
Goekoop-Ruiterman, Y.P.2
de Vries-Bouwstra, J.K.3
Peeters, A.J.4
van Krugten, M.V.5
Breedveld, F.C.6
Dijkmans, B.A.7
Allaart, C.F.8
-
8
-
-
3142771252
-
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis
-
Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004, 50:2082-2093.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 2082-2093
-
-
Welsing, P.M.1
Landewé, R.B.2
van Riel, P.L.3
Boers, M.4
van Gestel, A.M.5
van der Linden, S.6
Swinkels, H.L.7
van der Heijde, D.M.8
-
9
-
-
67449124635
-
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
-
Active-Controlled Study of Patients Receiving Infl iximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group
-
Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair; EW, . Active-Controlled Study of Patients Receiving Infl iximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009, 68:823-827. Active-Controlled Study of Patients Receiving Infl iximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 823-827
-
-
Smolen, J.S.1
Han, C.2
van der Heijde, D.M.3
Emery, P.4
Bathon, J.M.5
Keystone, E.6
Maini, R.N.7
Kalden, J.R.8
Aletaha, D.9
Baker, D.10
Han, J.11
Bala, M.12
St Clair13
, E.W.14
-
10
-
-
33750324355
-
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes
-
Landewe R, van der HD, Klareskog L, van VR, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006, 54:3119-3125.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 3119-3125
-
-
Landewe, R.1
van der, H.D.2
Klareskog, L.3
van, V.R.4
Fatenejad, S.5
-
11
-
-
84859517375
-
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
-
3329225, 22121130
-
Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2011, 71:687-693. 3329225, 22121130.
-
(2011)
Ann Rheum Dis
, vol.71
, pp. 687-693
-
-
Smolen, J.S.1
Avila, J.C.2
Aletaha, D.3
|